NasdaqGM:OCSPharmaceuticals
Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation
Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY data and advancement into registrational PIONEER trials.
See our latest analysis for Oculis Holding.
The FDA breakthrough therapy news has arrived alongside a 10.3% 7 day share price return and a 10.2% year to date share price return, while the 1 year total shareholder return of 17.8% and very...